Articles tagged with Graft Versus Host Disease
Researchers developed an AI-based tool called BIOPREVENT to identify patients at higher risk for chronic GVHD and dying from transplant-related causes. The tool combines immune biomarkers, clinical data, and machine learning to create a personalized risk estimate over time.
Researchers have found that patients with blood cancers can safely receive stem cell transplants from mismatched, unrelated donors using a protective regimen. The study's findings could make transplants accessible to nearly all patients with blood cancers, regardless of ancestry.
Researchers have discovered that a chemotherapy drug can improve outcomes in stem cell transplants when donors and recipients are unrelated and have significant genetic differences. The study showed comparable survival rates and lower risks of complications among patients receiving transplants with more or less extensive genetic mismat...
A new protocol for Treg expansion uses targeted immunotherapy to reduce transplant complications, boosting survival rates while preserving anti-cancer immunity. The protocol, led by Robert Levy, uses TL1A-Ig fusion protein and low-dose IL-2 to stimulate specific receptors on Tregs, promoting a safer environment for stem cell transplants.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
A Phase I clinical trial found that patients receiving itacitinib before and after a 'half-match' stem cell transplant experienced lower-than-expected rates of graft-versus-host disease, with no severe cases reported. The study also showed improved overall survival at one year, with 80% of patients remaining free from chronic graft-ver...
A study published in the Journal of Clinical Immunology found alemtuzumab to be safe and effective in treating Asian patients with inborn errors of immunity after allogeneic hematopoietic cell transplantation. The drug was shown to improve overall survival rates, with 94.7% of patients surviving post-transplantation.
Researchers found that specific microbes in the gut reduce graft versus host disease after stem cell transplantation. Patients with low microbial metabolite risk index had better survival rates, fewer graft vs. host reactions, and reduced relapses.
Researchers at UCLA have developed a new method to engineer more powerful immune cells that can potentially be used for 'off-the-shelf' cell therapy to treat challenging cancers. Gamma delta T cells with high expressions of CD16 surface marker exhibited increased ability to recognize and kill cancer cells.
A phase I pilot study investigates the feasibility of using potato starch as a dietary intervention to modify the gut microbiome in bone marrow transplant patients. The study found that more than 80% of participants took the supplement with no negative side effects, and butyrate levels were significantly higher in those who consumed it.
Dr. Hung Nguyen is studying how medium chain fatty acid foods like coconut oil and avocados affect GVHD severity and mortality in transplant patients. His goal is to develop a dietary approach that reduces inflammation and corticosteroid use, improving patient outcomes for blood cancers.
Researchers have developed a new standard for preventing graft-versus-host disease (GVHD) after stem cell transplant, showing improved efficacy and reduced side effects compared to the current gold standard. The new regimen achieved higher rates of patient survival without GVHD complications, making it a more effective option for patie...
Researchers at Baylor College of Medicine and University of Michigan report that altering gut microbiome is connected to increased oxygen levels in intestine following immune-mediated intestinal damage. Reducing intestinal oxygen levels alleviated the microbial imbalance and reduced the severity of GVHD.
A new Pitt study reframes understanding of graft-versus-host disease, suggesting that GVHD is locally maintained by donor T cells in target tissues. The research, published in Immunity, offers an alternative model that could guide development of novel therapies and improve outcomes for stem cell recipients.
Researchers found a drastic decrease in bacterial abundance on the skin of patients with graft-versus-host disease, while an increased occurrence of staphylococci was observed. This discovery may lead to improved treatment measures for GVHD, which affects approximately 30-70% of stem cell transplant recipients.
Researchers identified a specific gut bacterium responsible for antibiotic-induced GVHD after stem cell transplants. A sugar supplement was found to improve gut health by distracting the bacteria from attacking mucin in the intestinal lining, reducing complications such as GVHD.
Researchers engineered immune cells to control two major complications of leukemia treatment: graft-vs-host disease and cancer relapse. The approach, using a protein called OX40, showed promise in animal models, protecting against both conditions without severely impairing the immune system.
Human immune cells occupy certain tissues and remain there for years, contrary to previous belief. T cells found to be optimally adapted to their local environment, potentially supporting barrier function.
Researchers have developed a personalized dosing regime for anti-thymocyte globulin (ATG) to improve the success of stem cell transplants in children with leukemia. The new approach led to better immune recovery and higher survival rates compared to standard treatment.
Sophie Paczesny's research aims to validate biomarker panels that help doctors predict chronic GVHD risk and adjust immune suppression treatments accordingly. The study uses machine learning algorithms to analyze stored plasma and blood cell samples from over 1,300 BMT recipients.
A new graft strategy has reduced chronic graft-versus-host disease in leukemia patients by depleting naïve T cells from donor blood. The approach has shown promising results, with only 7% of patients developing chronic GVHD compared to 30-60% with standard treatment.
Chronic graft-versus-host disease (cGVHD) causes skin thickening due to the production of TGFβ1 by apoptotic keratinocytes stimulated by interferon-γ, according to researchers at the University of Tsukuba.
Sylvester researchers have identified a potential protein target, STING, that may help mitigate graft versus host disease in stem cell transplants. In preclinical models, inhibiting the STING pathway reduced symptoms of GVHD.
A University of Colorado Cancer Center study shows cord blood transplants to be comparable to matched sibling donors in terms of survival outcomes, with significantly fewer complications due to chronic graft-versus-host disease. Cord blood patients also experienced a lower rate of relapse in certain populations.
A new study suggests that rare, harmful genetic mutations present in healthy donors' stem cells can be passed on to cancer patients, causing heart damage, graft-versus-host disease and new leukemias. The study analyzed DNA samples from 25 AML patients and their matching donors, revealing 44% of donors had at least one harmful mutation.
Researchers discovered that baricitinib prevented graft-versus-host disease and even reversed established cases in mouse studies. The drug boosts immune cells to fight cancer while keeping donor T cells from attacking vital organs.
Abatacept significantly improves survival and disease-free rates for patients with severe acute graft-versus-host disease, a life-threatening complication of stem cell transplantation. The treatment reduces the occurrence of acute GvHD from 32% to 3% in pediatric and adult patients.
Researchers at Mount Sinai Health System have developed an algorithm that predicts bone marrow transplant patients' risk of developing graft-versus-host disease. The 'MAGIC algorithm' uses two proteins in blood samples to determine a patient's risk, allowing for early intervention and potentially saving lives.
A University of Colorado Cancer Center study found cord blood transplants had a lower incidence of severe chronic graft-versus-host disease and allowed patients to discontinue immunosuppression sooner. The results suggest cord blood may be equal to or better than matched, unrelated donor transplants.
Researchers have discovered a rabbit virus that can deliver a one-two punch, killing some kinds of cancer cells while eliminating a common complication of bone marrow transplants. The myxoma virus can quell graft-versus-host disease and destroy cancer cells, offering new hope for patients with blood cancers.
Researchers have found a molecular 'switch' that safely controls severe side effects associated with haploidentical stem cell transplantation. The switch, inducible caspase 9 (iC9), is activated by a single dose of bio-inert chemical and clears symptoms without jeopardizing graft function.
Researchers have identified a biomarker called ST2 that can predict the risk of graft-versus-host disease in stem cell transplant patients. Patients with high ST2 levels are more likely to experience severe immune responses and die within six months of the transplant.
Researchers have discovered a new method to prevent graft-versus-host disease, a severe complication of bone marrow transplants. By inhibiting the Notch signaling pathway, they were able to block the disease without compromising the anti-cancer effects of transplantation.
Research reveals a link between Glyoxylase 1 and increased anxiety in mice, with implications for potential therapeutic targets. Additionally, studies provide hope for new treatments for the rare disease Beare-Stevens syndrome and graft versus host disease.
Scientists have discovered that the platelet activating factor receptor plays a crucial role in graft-versus-host disease, which can cause significant tissue damage and mortality. Blocking this receptor may lead to reduced tissue injury and improved survival rates for patients undergoing bone marrow transplants.
A new anti-inflammatory agent called ATL146e has been shown to limit and reverse the progression of graft-versus-host disease after bone marrow transplants. This breakthrough could make these potentially curative transplants safer and more widely used for individuals with inherited immunodeficiency diseases.
Researchers developed a new approach to prevent graft-versus-host disease and enhance immune recovery after haploidentical transplants. The study showed long-term protection from graft-versus-host disease in 25 of 26 patients, with improved immune system reconstitution.
A novel method for imperfectly matched stem cell transplants has shown a striking response that can suppress graft-versus-host disease. The technique, known as co-stimulatory blockade, unleashes a surge of regulatory T-cells that dampen the immune reaction.
Researchers at UNC School of Medicine have discovered that TH17 cells, a subset of immune cells, can cause transplant rejection. The study's findings may lead to the development of targeted therapies to prevent graft-versus-host disease, which is a major complication of transplants.
A phase I/II study found that intrabone administration of unrelated cord-blood cells increased the number of patients who could receive hematopoietic stem-cell transplantation. The technique reduced the incidence of graft-versus-host disease, a common complication of allogeneic transplants.
Eating uncooked fish dishes is associated with an increased risk of developing cholangiocarcinoma, a type of liver cancer caused by the SE Asian liver fluke Opisthorchis viverrini. In Thailand alone, 6 million people are thought to be infected with the parasite.
Researchers used gene-expression profiling to identify donors with a strong reaction against recipient cells, leading to increased risk of graft-versus-host disease. Accurate MHC haplotype matching reduced mismatching-related risks.
A new blood transplant method has shown significant promise in reducing the risk of fatal side effects associated with cancer treatment. The Stanford study found that the therapy successfully boosted regulatory T cells, minimizing graft-versus-host disease without compromising its ability to kill cancerous cells.
Researchers at UT Southwestern are developing a new procedure to eliminate graft-versus-host disease in bone-marrow transplants while retaining anti-leukemic activity. The approach uses immunotoxins to selectively target and eliminate harmful immune cells, with promising results in clinical trials.